12:00 AM
 | 
Oct 29, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Status

SP-333: Phase I started

Synergy began a single-blind, placebo-controlled, U.S. Phase I trial to evaluate single ascending-doses of 0.1, 0.3, 1, 3, 10, 30 and 60...

Read the full 88 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >